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Ethnopharmacological relevance: From seeds of Carapa guianensis the Amazon native people extracts the
andiroba oil, which is traditionally used as febrifuge, anti-malarial, insecticidal and repellant. The non-
saponiﬁable fraction separated from the oil is rich in limonoids, which assigns its pharmacological
effects.
Materials and methods: The andiroba oil and its limonoid-rich fraction were submitted to in vitro
antiplasmodial bioassay using W2 and Dd2 strains of Plasmodium falciparum. The acute toxicity of
andiroba oil was evaluated. The limonoid-rich fraction was subjected to fractionation and identiﬁed its
major constituents.
Results: Andiroba oil and its limonoid-rich fraction inhibited the growth of W2 clone in 100%, between
24 and 72 h, at concentrations of 8.2 mg/mL and 3.1 mg/mL, respectively. Under the same conditions, the
parasitaemia of Dd2 clone provoked by the andiroba oil showed inhibition of 31% (IC50 482 mg/mL)
with a time-dependent relationship of 24 h and inhibition of 88% (IC50 8.4 mg/mL) after 72 h, while for
the limonoid-rich fraction the inhibition of Dd2 clone was 56% (IC50 2.8 mg/mL) at 24 h and 82% (IC50
0.4 mg/mL) after 72 h. Andiroba oil in acute toxicity test with a ﬁxed dose (LD50 42000 mg/kg) was not
toxic The limonoids identiﬁed in the oil were gedunin, 6a-acetoxygedunin, 7-deacetoxy-7-oxogedunin,
7-deacetylgedunin, 1,2-dihydro-3b-hydroxy-7-deacetoxy-7-oxogedunin and andirobin. Gedunin and
derivatives has been reputed as anti-malarials.
Conclusion: The results support the traditional use of andiroba oil as antiplasmodial, which additionally
proved not to be toxic in bioassays conducted with mice.
& 2012 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction
About 40% of the world’s population lives in countries where
the malaria is endemic and more than 300 million people are
suffering from the disease every year (WHO, 2008). Most cases of
malaria have been reported for the sub-Saharan Africa and it is
responsible for the almost 1 million deaths each year. Outside
Africa malaria still claims for more than 100 thousand lives each
year. In Latin America, reaching 99%, the largest number of cases
is veriﬁed in the Brazilian Amazon, with an incidence of 400 to
700 thousand cases a year. According to the Brazilian Ministry of
Health, just in the Amazonas, Rondoˆnia and Para´ states, wasac- ~ao em Quı´mica, Universi-
5-900 Bele´m, Brazil.
der the Elsevier OA license.registered about 350 thousand cases of malaria in 2007
(Ministe´rio da Sau´de, 2008).
The etiological agents of malaria are protozoans that belong to
four parasite species pathogenic to humans: Plasmodium falciparum, P.
vivax, P. ovale, and P. malariae. Plasmodium falciparum is the parasite
responsible for most cases of malaria (80% worldwide) and for the
most severe forms of the disease, frequently fatal.
The resistance of P. falciparum to the available drugs has
become the most important threat to the effective control of the
disease. Naturally occurring populations are known to vary
considerably in their relative sensibility to meﬂoquine. Chloro-
quine-resistant strains of P. falciparum occur in all endemic areas
except in Panama, Mexico, Hispaniola and parts of China, as well
as multidrug-resistant strains exist in Southeast Asia, South
America, and in the sub-Saharan Africa (Griffth et al., 2007). The
chloroquine-resistant parasites accumulate low levels of the drug
compared to drug-sensitive parasites. It is understood that the
resistance of parasites is due to exclusion of the drug from its site
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The boundary between Thailand and Cambodia, with respect to
malaria, has become an area of concern with the emergence of
numerous cases of resistance to the drug artemisinin. For this
reason, some warning signs have been sent to the entire world by
the WHO as a result of human migration in the region that is
greatly facilitated and this differential resistance can spread
throughout the African continent (World Health Organization
(WHO), 2007). The resistance to artemisinin was observed by
the change and selective inhibition of protein-type ATPase in the
genome of P. falciparum (Eckstein-Ludwig et al., 2003; Mugittu
et al., 2006).
The spread of resistance of the mosquito vector to currently
available insecticides and the limited success of potential anti-
malarial vaccines contribute to the urgent necessity of ﬁnding
new chemotherapeutic agents for the treatment of malaria, in
particular, against P. falciparum, the strain responsible of the most
severe forms of malaria (Corbett et al., 2004). There is a consensus
that new drugs to treat malaria are urgently needed. These drugs
need to have schizontocidal and gametocytocidal activities for the
blood and tissues, as well as they must be inexpensive, safe, long-
acting and effective in preventing relapses. Treatment is aimed to
the interruption of blood schizogony, responsible for the patho-
genesis and clinical manifestations of infection (Fundac- ~ao
Nacional da Sau´de (FUNASA), 2001).
The search for novel compounds effective against Plasmodium
strains resistant to widely used synthetic drugs has led to
increased interest in new and existing information about malaria
remedies from natural sources (Phillipson and Wright, 1991;
Angerhofer et al., 1992; Wells et al., 2009). Natural products
comprising alkaloids, lignans, triterpenes, coumarins, ﬂavonoids
and limonoids isolated from medicinal plants and used world-
wide were examined in vitro for antimalarial activity against P.
falciparum (Khalid et al., 1986; Leaman et al., 1995; Batista et al.,
2009; Nogueira and Lopes, 2011). Some Meliaceae species in
Tropical America, as Cedrela odorata L., Carapa guianensis Aubl.,
and Swietenia mahagoni (L.) Jacq., have been used in traditional
medicine for the treatment of fevers. (Ayensu, 1981). MacKinnon
et al. (1997) examined extracts from 22 Meliaceae species, by
characterizing their in vitro antiplasmodial activities against the
clones chloroquine-sensitive (D6) and chloroquine-resistant (W2)
of P. falciparum.
The Meliaceae family is rich in limonoids, highly oxygenated
tetranortriterpenoid compounds that are reported to possess a
wide range of biological activities, such as insecticidal, antifee-
dant and growth-regulator on insects, antibacterial, antifungal,
antimalarial, and antiviral (Roy and Saraf, 2006). Gedunin, nim-
bin, nimbolide and many other limonoids isolated from Azadir-
achta indica, Carapa odorata, Guarea multiﬂora, Khaya grandiﬂora
and K. grandifoliola have been identiﬁed for their in vitro anti-
malarial activities on P. falciparum (Bickii et al., 2000; Kayser
et al., 2003; Saxena et al., 2003). Finally, new antiplasmodial
limonoids known as ceramicines were reported from Chisocheton
ceramicus C. DC. (Mohamad et al., 2009).
The species Carapa guianensis Aubl., known as andiroba, is
another rich source of limonoids. It is an oilseed crop that grows
wild throughout South America. From its seeds the native people
of the Amazon extracts the andiroba oil, traditionally used as
febrifuge, anti-bacterial, anti-parasitic and anti-inﬂammatory, as
well as insecticidal, pain-relieving, and repellant (Tropical
Plant Database, 2012, www.rain-tree.com/andiroba.htm). The
andiroba oil is a source of fatty acids, such as oleic, palmitic,
stearic and linoleic acids. The non-saponiﬁable part of the oil,
between 2 and 5%, basically consists of a rich fraction contain-
ing limonoids. The compounds methyl angolensate, 7-deaceto
xy-7-oxogedunin, deacetylgedunin, 6a-acetoxygedunin, gedunin,andirobin, 17b-hydroxyazadiradione, 1,2-dihydro-3b-hydroxy-7-
deacetoxy-7-oxogedunin and xyloccensin were previously iso-
lated from C. guianensis by various chromatographic techniques
(Ambrozin et al., 2006; Silva et al., 2009).
In view of the importance of Meliaceae in the search for
compounds that may act as anti-malarial drugs, the aim of this
paper is to report the in vitro evaluation of the andiroba oil and its
limonoid-rich fraction against chloroquine-resistant P. falciparum
strains, as well as the fractionation and identiﬁcation of the main
compounds existing in the limonoid-rich fraction. In addition the
acute toxicity of andiroba oil was also determinate.2. Materials and methods
2.1. Andiroba oil (AO)
It was obtained by traditional process, as it is done by native
peoples of the upper Tocantins River, Brazil. The seeds (500 g) of
andiroba were collected in the campus of University of Para´, in
March 2008, boiled in a pot of water, stored for some two weeks
until start to get rotten (the time to occur the hydrolysis process),
and then subjected to pressing and ﬁltering to separate the oil
(60 g). This specimen was identiﬁed with an authentic voucher
(MG 144540) of Carapa guianensis Aubl., deposited in the herbar-
ium of Museu Emı´lio Goeldi, Bele´m, PA, Brazil.
2.2. Limonoid-rich fraction (LRF)
After being extracted, the andiroba oil (10 g) was submitted to
fractionation in a silica gel chromatographic column (Merck 60,
0.040-0.063 mm), using for elution a gradient mixture of hexane
and ethyl acetate and yielding a limonoid-rich fraction (0.4 g),
according to their similarity in TLC plates (Merck 60G). After
pretreatment in C18 SPE cartridge it was subjected to HPLC
reversed-phase (Shimadzu, LC-8A and UV detector) using gradient
mixture of acetonitrile and ultra-pure water as mobile phase and
keeping the ﬂow at 1.0 mL/min and detection at 217 nm, yielding
six pure compounds (1–6). The detection and identiﬁcation of the
limonoids were performed by TLC and HPLC-DAD with co-injec-
tion of authentic samples, as well as by the 1H and 13C NMR
chemical shifts. The TLC plates were revealed with cerium sulfate/
sulfuric acid reagent, after heating to 100 1C. The HPLC-DAD
conditions were mentioned above.
2.3. Antiplasmodial assay
The clones of Plasmodium falciparum – Dd2 (resistant to
chloroquine, meﬂoquine and piremetamin) and W2 (resistant to
chloroquine and sensitive to meﬂoquine) were kept in continuous
cultures of human erythrocytes, suspended in RPMI 1640 and
supplemented with 10% human serum, according the method
described by Trager and Jensen (1976). The antiplasmodial
activity of the andiroba oil and its limonoid-rich fraction were
performed in 96-well tissue culture plates as previously described
(Rieckmann, 1980; Carvalho et al., 1991; Mitaine-Offer et al.,
2002). Twofold serial dilutions of limonoid-rich fraction dissolved
in sterile methanol, and andiroba oil dissolved in DMSO solution,
were placed in micro titer plates and diluted with the culture
medium (RPMI 1640 plus 10% human serum). A suspension of
parasitized erythrocytes (0.5–1% parasitaemia, 2.5% hematocrit)
containing mainly trophozoites was added to the wells to reach a
ﬁnal volume of 100 mL. For andiroba oil were used the concentra-
tions 820, 82, 8.2, 0.82 and 0.082 mg/mL, while for limonoid-rich
fraction the concentrations were 100, 50, 25, 12.5, 6.25 and
3.125 mg/mL. Chloroquine (clone Dd2) and quinine (clone W2)
Table 1
Inhibition percentages of the andiroba oil and limonoid-rich fraction against the
W2 clone.
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as negative controls. The plates were incubated at 37 1C and after 24
and 48 h the culture medium was replaced by fresh medium with or
without test samples. Samples were taken 24 h, 48 h and 72 h later,
smeared, Giemsa stained and microscopically examined to determine
the percentage of parasitaemia by counting 2000 erythrocytes. All
material used in this essay was endotoxin free. Results were
expressed as the mean IC50 of three independent experiments for
each sample. The Student t test was used to compare the inhibition of
the two different P. falciparum strains.
2.4. Animals
Female Swiss albino mice (20–30 g) were obtained from colo-
nies maintained in the Instituto Evandro Chagas (Bele´m, Brazil) and
kept under environmentally controlled conditions (24 1C; 12–12 h
dark/light cicle) for seven days. Food was withheld overnight prior
to experiments while water was still provided ad libitum. The
experimental procedures and use of animals was approved by
Animal Experimentation Ethics Committee of Federal University
of Para´.
2.5. Acute toxicity
The test of acute toxicity was performed according the
National Institute of Environmental Health Sciences (NIEHS 2001).
Mice were divided into three groups (10 animals by group). The
groups received by oral gavages (single dose): 100 mL of ultra pure
water; 100 mL of water and tween 20 (1%); and 100 mL of a solution
containing water (490 mL), andiroba oil (500 mL) and tween 20
(10 mL), corresponding to a dose of 2.0 g/kg. The animals were
observed for the ﬁrst three hours and every 24 h for 14 days. Body
weight and clinical evaluation of the animals were measured daily.
Hematological and biochemical parameters were made on the
14th day.Samples Concentration (mg/mL) W2 strain (% inhibition)
24 h 48 h 72 h
AO 8.2 100 100 100
LRF 3.1 100 100 100
Quinine 0.016 71 73 75
AO¼andiroba oil; LRF¼ limonoids-rich fraction.3. Results
3.1. Limonoid-rich fraction
The extraction performed in the seeds (500 g) of C. guianensis
yielded 12% of andiroba oil (60 g). The fractionation of andirobaFig. 1. Limonoids isolateoil (10 g) on silica chromatographic column provided a yield of
3.5% for the limonoid-rich fraction (350 mg). The limonoids
occurring in the limonoid-rich fraction (compounds 1–6) were
identiﬁed by co-injection of authentic standards using HPLC-DAD
and TLC, as well as by the 1H and 13C NMR chemical shifts
(Ambrozin et al., 2006; Silva et al., 2009). The following limonoids
were isolated and identiﬁed in the limonoid-rich fraction: gedu-
nin (1) (24 mg), 6a-acetoxygedunin (2) (44 mg), 7-deacetoxy-7-
oxogedunin (3) (21 mg), 7-deacetylgedunin (4) (22 mg), 1,2-
dihydro-3b-hydroxy-7-deacetoxy-7-oxogedunin (5) (25 mg) and
andirobin (6) (24 mg) (Fig. 1).
3.2. Antiplasmodial assay
Andiroba oil and its limonoid-rich fraction inhibited the
growth of W2 clone in 100%, between 24 and 72 h, at concentra-
tions of 8.2 mg/mL and 3.1 mg/mL, respectively. Table 1 compares
these results with those of quinine, the drug used as standard.
Under the same conditions, the parasitaemia of Dd2 clone pro-
voked by the andiroba oil showed inhibition of 31% (IC50482 mg/
mL) with a time-dependent relationship of 24 h, followed by
inhibition of 71% (IC50 9.4 mg/mL) at 48 h and inhibition of 88%
(IC50 8.4 mg/mL) after 72 h. For the limonoid-rich fraction the
inhibition of Dd2 clone was 56% (IC50 2.8 mg/mL) at 24 h, 64% (IC50
2.4 mg/mL) at 48 h and 82% (IC50 0.4 mg/mL) after 72 h. Table 2
compares these results with those of chloroquine, the drug used
as standard.
For Dd2 clone, in both experiments with andiroba oil and
limonoid-rich fraction, the ﬁnal response at 72 h (IC50 8.4 mg/mL
and IC50 0.4 mg/mL) was more positive than the initial response of
24 h (IC50 482 mg/mL and IC50 2.8 mg/mL). A concentration-d from andiroba oil.
Fig. 2. Concentration-response curve for the andiroba oil (AO) and limonoid-rich
fraction (LRF) against the Dd2 clone.
Table 3
Effects of andiroba oil on hematological and biochemical parameters by oral route
in mice.
Group 1* Group 2* Group 3*
Hematological parameters
Erythrocytes (106 mL)1 8.7370.2 8.3570.1 8.3870.3
Hemoglobin (g/dL) 13.770.2 13.670.21 14.170.1
Hematocrit (%) 42.670.4 42.270.7 42.670.4
MCV (fL) 50.670.8 49.670.9 51.971.9
MCH (pg) 17.170.7 17.170.4 17.570.5
MCHC (g/dL) 31.470.3 30.870.2 31.270.2
Leukocytes (103 mL)1 7.7470.2 7.6670.2 8.0470.1
Biochemical parameters
Glicose (mg/dL) 88.274.0 87.273.68 83.172.79
AST (IU/L) 64.472.5 64.571.8 69.272.6
ALT (IU/L) 49.872.3 49.671.9 51.871.7
Creatinine (mg/dL) 0.5670.02 0.6270.03 0.5870.02
Group 1: water (100 mL, control); Group 2: water (100 mL)þtween (1%); Group 3:
water (490 mL)þtween (10 mL)þandiroba oil (500 mL). The values are expressed as
mean7S.E.M (n¼10 animals/group).
n No signiﬁcant difference between the parameters by analysis of variance,
ANOVA.
Table 2
Inhibition percentages and IC50 values of the andiroba oil and limonoid-rich
fraction against the Dd2 clone.
Samples Concentration (mg/mL) Dd2 strain
% Inhibition IC50 (mg/mL)
24 h 48 h 72 h 24 h 48 h 72 h
AO 8.2 31 71 88 482 9.4 8.4
LRF 3.1 56 64 82 2.8 2.4 0.4
Chloroquine 0.031 10 35 60 41 0.1 0.01
AO¼andiroba oil; LRF¼ limonoids-rich fraction.
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different time-points, was constructed to substantiate the deter-
mination of IC50 values (see Fig. 2).
3.3. Acute toxicity
The acute toxicity indicated that andiroba oil by oral route of a
single dose of 2.0 g/kg did not produce any sign of toxic effect or
death in mice during 14 days of observation. In addition, no
alteration in their hematological and biochemical parameters was
detected, as can be seen in Table 3.4. Discussion
The results for the andiroba oil and its limonoid-rich fraction
are in agreement with those previously reported to Meliaceae
species that occur in Africa and Asia, in which the antiplasmodial
effects of crude extracts of Azadirachta indica, Carapa odorata,
Guarea multiﬂora, Khaya grandiﬂora and K. grandifoliola showed
IC50 values varying from 1.0 to 10 mg/mL (Khalid et al., 1986;
Phillipson and Wright, 1991; Bickii et al., 2000), at same range of
activity observed for the W2 clone in our experiments. The
inhibition of parasite growth was 100% for the W2 clone (resistant
to chloroquine and sensitive to meﬂoquine), using andiroba oil
and its limonoid-rich fraction at concentrations of 8.2 mg/mL and
3.1 mg/mL, respectively, in comparison to quinine (standard drug,
0.016 mg/mL). It is likely that the parasite inhibition still be 100%
if the concentrations of andiroba oil and limonoid-rich fractionare smaller. The same observation could be made to the inhibition
of the Dd2 clone (resistant to chloroquine and meﬂoquine).
Despite the low concentration of chloroquine (0.031 mg/mL,
standard drug) its inhibition was only 60%, while the andiroba
oil and its limonoid-rich fraction showed higher inhibition values,
88% (IC50 8.4 mg/mL) and 82% (IC50 0.4 mg/mL), respectively, after
72 h. This latter value is comparable to that of other limonoids
from Meliaceae, as ceramicine B (IC50 0.23 mg/mL) active against
the 3D7 clone and isolated from Chisocheton ceramicus occurring
in Malaysia (Mohamad et al., 2009) and as trichirubine A (IC50
0.3 mg/mL) active against the FcB1 clone and identiﬁed in Trichilia
rubescens existing in Uganda, Africa (Krief et al., 2003). Moreover,
among the limonoids, gedunin (1) has been regarded as one of the
most active compounds tested in in vitro antimalarial assays,
whose IC50 values (0.7 to 1.25 mg/mL) inhibit the W2 and KI
clones, resistant to chloroquine (Khalid et al., 1989; MacKinnon
et al., 1997; Bickii et al., 2000). The limonoid derivatives 7-dea-
cetyl-7-oxogedunin (3) and 7-deacetylgedunin (4), previously
isolated from the roots of Pseudocedrela kotschyi and occurring
in Mali, have been reported to display moderate antimalarial
activity (IC50¼1.36 and 1.77 mg/mL, respectively) (Hay et al.,
2007), which should also contribute to the antiplasmodial activity
observed in andiroba oil and limonoid-rich fraction.
Some criteria have been used in establishing the in vivo anti-
plasmodial activity of crude extract and compounds. Basco et al.
(1994) adopted the following criteria: IC50 o10 mg/mL, good
activity; IC50 of 10–50 mg/mL, moderate activity; IC50 of 50–
100 mg/mL, low activity; and IC504100 mg/mL, inactive. Batista
et al. (2009) have used combined criteria: IC50 o1 mM, excellent/
potent activity; IC50 of 1–20 mM, good activity; IC50 of 20–100 mM,
moderate activity; IC50 of 100–200 mM, low activity; and IC50
4200 mM, inactive. In view of our results and the criteria presently
adopted, we can consider the andiroba oil and its limonoid-rich
fraction in the range from good to excellent antiplasmodial activity.
According to the experiments, it can be suggested that acute
toxicity of andiroba oil in mice is practically null by oral route. At
the dose used is possible to estimate a LD50 42.0 g/kg. In a
previous study the dose of 5.0 mg/kg was administered to rats
and not produced toxicity or deaths of the animals (Costa-Silva
et al., 2008). Therefore, in toxicity bioassays using mice and rats
could be accepted doses greater than 2.0 g/kg and 5.0 g/kg,
respectively. At the same time, this result precludes the possibi-
lity of which clones W2 and Dd2 were eliminated by the toxicity of
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andiroba oil.
The different responses of the clones of P. falciparum to the
in vitro antimalarial assays can be explained by their genetics,
since the chloroquine-resistant clones (as W2 and Dd2 strains)
may have their genes modiﬁed by the action of the drug and thus
altering their sensitivity to chloroquine (Viana et al., 2006).5. Conclusion
The andiroba oil and its limonoid-rich fraction, both derived
from Carapa guianensis, a Meliaceae species with occurrence in
the Brazilian Amazon, showed a signiﬁcant antiplasmodial activ-
ity against the clones W2 and Dd2 of Plasmodium falciparum. For
gedunin (1), 6a-acetoxygedunin (2), 7-deacetoxy-7-oxogedunin
(3), 7-deacetylgedunin (4), 1,2-dihydro-3b-hydroxy-7-deacetoxy-
7-oxogedunin (5) and andirobin (6), the limonoids that were
identiﬁed from the non-saponiﬁable part of the andiroba oil, we
are attributing this anti-plasmodial activity.Acknowledgments
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